Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 16.250-16.250 for the period, compared to the consensus estimate of 16.910. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HUM. Truist Financial raised their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday. Barclays boosted their price objective on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Finally, Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and raised their target price for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $296.84.

Humana Stock Down 3.8 %

Shares of Humana stock opened at $256.69 on Wednesday. The company’s 50 day moving average price is $273.00 and its 200-day moving average price is $295.72. Humana has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market capitalization of $30.91 billion, a price-to-earnings ratio of 22.74, a P/E/G ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities research analysts forecast that Humana will post 16.11 EPS for the current year.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.